Bristol-Myers Squibb and Pfizer report positive Eliquis data

Bristol-Myers Squibb and Pfizer have reported positive phase III clinical trial data supporting the efficacy of their anticoagulant therapy Eliquis over a one-year period.

Results from the Amplify-EXT trial showed the drug's superiority in preventing recurrent venous thromboembolism and all-cause death compared to placebo.

This means the therapy was able to meet its primary efficacy endpoint by a statistically significant margin, while its safety performance was also shown to be robust.

Lead investigator Dr Giancarlo Agnelli, professor of internal medicine at the University of Perugia, said: "Eliquis reduced the composite risk of recurrent venous thromboembolism and total mortality without an increase in major bleeding versus placebo."

Eliquis is the result of a major global collaboration agreement between Bristol-Myers Squibb and Pfizer that was signed in 2007.

Last month, the companies attended the scientific sessions of the American Heart Association to highlight clinical data showing the efficacy of the drug compared to warfarin.